<?xml version="1.0" encoding="UTF-8"?>
<p id="p0100">An important consequence of the breadth and depth of the COVID-19 pandemic is that frequently multiple trials are being concurrently conducted evaluating related regimens in related clinical settings. When separate DMCs would be monitoring these concurrent trials evaluating closely related clinical questions, while DMCs usually do not discuss the emerging data outside of their committee, there could be important benefits if DMCs had the ability to share key insights with each other, such as unblinded information on adverse events by intervention group [
 <xref rid="bib18" ref-type="bibr">18</xref>]. This would enable some of the beneficially broadened insights achieved in settings where sponsors have engaged a single DMC to monitor multiple concurrently conducted trials that are part of a clinical development program for a drug or biologic.
</p>
